Free Trial
NASDAQ:ARTV

Artiva Biotherapeutics Q3 2024 Earnings Report

Artiva Biotherapeutics logo
$3.16 -0.11 (-3.36%)
Closing price 04:00 PM Eastern
Extended Trading
$3.32 +0.16 (+4.91%)
As of 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artiva Biotherapeutics EPS Results

Actual EPS
-$0.92
Consensus EPS
-$0.68
Beat/Miss
Missed by -$0.24
One Year Ago EPS
N/A

Artiva Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.30 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artiva Biotherapeutics Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Artiva Biotherapeutics' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Thursday, November 6, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Artiva Biotherapeutics Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
Artiva (ARTV) Q2 Loss Widens 19.7%
See More Artiva Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artiva Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artiva Biotherapeutics and other key companies, straight to your email.

About Artiva Biotherapeutics

Artiva Biotherapeutics (NASDAQ:ARTV), a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

View Artiva Biotherapeutics Profile

More Earnings Resources from MarketBeat